|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 5: Baseline Weight Promoting Medication Utilization by Race/Ethnicity** |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| **Medications** | **All women  in sample** | **American Indian/Alaska Native** | **Asian/Pacific  Islander** | **African American** | **Hispanic** | **Non-Hispanic White** | **Unknown** |
|  | **N=76,053** | **N=292** | **N=2,277** | **N=5,542** | **N=2,476** | **N=64,750** | **N=806** |
| **Antidepressants** | 5,133 6.7% | 23 7.9% | 45 2% | 208 3.8% | 172 6.9% | 4,639 7.2% | 46 5.7% |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | 2,717 3.6% | 9 3.1% | 21 0.9% | 90 1.7% | 81 3.3% | 2,489 3.8% | 27 3.3% |
| Tricyclic Agents | 2,278 3% | 13 4.5% | 23 1% | 111 2% | 81 3.3% | 2,033 3.1% | 17 2.1% |
| Misc.Antidepressants | 377 0.5% | 2 0.7% | 1 0% | 13 0.2% | 16 0.6% | 341 0.5% | 4 0.5% |
| **Antipsychotics** | 21 0.03% | 0 0% | 1 0.04% | 3 0.06% | 2 0.08% | 15 0.02% | 0 0% |
| Benzisoxazoles | 21 0.03% | 0 0% | 1 0.04% | 3 0.06% | 2 0.08% | 15 0.02% | 0 0% |
| Thienbenzodiazepines | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
| **Beta Blockers** | 6,017 7.9% | 18 6.2% | 154 6.8% | 413 7.6% | 132 5.3% | 5,237 8.1% | 63 7.8% |
| Beta Blockers Cardio-Selective | 4,511 5.9% | 16 5.5% | 123 5.4% | 324 5.9% | 106 4.3% | 3,898 6% | 44 5.5% |
| Beta Blockers Non-Selective | 1,511 2% | 2 0.7% | 31 1.4% | 89 1.6% | 26 1.1% | 1,344 2.1% | 19 2.4% |
| **OTC Insulin** | 648 0.9% | 5 1.7% | 13 0.6% | 186 3.4% | 35 1.4% | 404 0.6% | 5 0.6% |
| **Glucocorticosteroids** | 951 1.3% | 3 1% | 20 0.9% | 112 2.1% | 36 1.5% | 771 1.2% | 9 1.1% |
|  |  |  |  |  |  |  |  |
| Data are numbers and column percentages |  |  |  |  |  |  |  |

OTC- Over the Counter